Clinical onset and course, response to treatment and outcome in 24 patients with the cblE or cblG remethylation defect complemented by genetic and in vitro enzyme study data
- 796 Downloads
The cobalamin E (cblE) (MTRR, methionine synthase reductase) and cobalamin G (cblG) (MTR, methionine synthase) defects are rare inborn errors of cobalamin metabolism leading to impairment of the remethylation of homocysteine to methionine.
Information on clinical and laboratory data at initial full assessment and during the course of the disease, treatment, outcome and quality of life was obtained in a survey-based, retrospective study from physicians caring for patients with the CblE or CblG defect. In addition, data on enzyme studies in cultured skin fibroblasts and mutations in the MTRR and MTR gene were analysed.
In 11 cblE and 13 cblG patients, failure to thrive, feeding problems, delayed milestones, muscular hypotonia, cognitive impairment and macrocytic anaemia were the most frequent symptoms. Delay in diagnosis depended on age at first symptom and clinical pattern at presentation and correlated significantly with impaired communication abilities at follow-up. Eighteen/22 patients presented with brain atrophy or white matter disease. Biochemical response to treatment with variable combinations of betaine, cobalamin, folate was significant. The overall course was considered improving (n = 8) or stable (n = 15) in 96 % of patients, however the average number of CNS symptoms per patient increased significantly over time and 16 of 23 patients were classified as developmentally delayed or severely handicapped. In vitro enzyme analysis data showed no correlation with outcome. Predominantly private mutations were detected and no genotype– phenotype correlations evident.
The majority of patients with the cblE and cblG defect show limited clinical response to treatment and have neurocognitive impairment.
KeywordsCobalamin Macrocytic Anaemia Muscular Hypotonia Haemolytic Uremic Syndrome External Hydrocephalus
We thank all patients and their families who gave informed consent to include their data. This work was supported by the Swiss National Science Foundation [grant number 31003A_138521 to M.R.B. and B.F.] and the Rare Disease Initiative Zurich (radiz), a clinical research priority program for rare diseases of the University of Zurich, Switzerland. Institutional support to P.J and V.K. was provided by projects RVO VFN64165 and PRVOUK-P24/LF1/3.
Compliance with ethics guidelines
Conflict of interest
Human and animal rights and informed consent
All procedures followed were in accordance with the ethical standards of theresponsible committee on human experimentation (institutional and national) and with the HelsinkiDeclaration of 1975, as revised in 2005. Informed consent was obtained from all patients for beingincluded in the study.
- Kandula T, Peters H, Fahey M (2014) Cobalamin E defect, a rare inborn error of vitamin B12 metabolism: Value of early diagnosis and treatment. Clin Neurosci2014 May 17. pii: S0967-5868(14)00161-1. doi: 10.1016/j.jocn.2013.12.030
- Kömhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, Berger RM (2013) Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics 132(2):e540–e544Google Scholar
- Suormala T, Baumgartner MR, Coelho D, Zavadakova P, Kozich V, Koch HG, Berghäuser M, Wraith JE, Burlina A, Sewell A, Herwig J, Fowler B (2004) The cblD defect causes either isolated or combined deficiency of methylcobalamin and adenosylcobalamin synthesis. J Biol Chem 279:42742–9CrossRefPubMedGoogle Scholar
- Zavadakova P, Fowler B, Zeman J, Suormala T, Pristoupilová K, Kozich V (2002) CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families. J Inherit Metab Dis 25(6):461–76, Erratum in: J Inherit Metab Dis 2003;26(1):95CrossRefPubMedGoogle Scholar